Patents Examined by Patricia Duffy
  • Preparation of high-purity gadobutrol
    Patent number: 10072027
    Abstract: What is described is a process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration. The process is carried out using specifically controlled crystallization conditions. The more recent developments in the field of the gadolinium-containing MR contrast agents (EP 0448191 B1, CA Patent 1341176, EP 0643705 B1, EP 0986548 B1, EP 0596586 B1) include the MRT contrast agent gadobutrol (Gadovist® 1.0) which has been approved for a relatively long time in Europe and more recently also in the USA under the name Gadavist®.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: September 11, 2018
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Modified toxins
    Patent number: 10059750
    Abstract: The present application relates to compositions of modified toxins exhibiting cytotoxicity and/or reduced immunogenicity. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease. A modified diphtheria toxin or fusion protein may be administered with one or more other agents.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 28, 2018
    Assignee: ANGELICA THERAPEUTICS, INC.
    Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Alyson Jane Rust, Simon Keen
  • Detoxified immunogens
    Patent number: 10058600
    Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: August 28, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Laura Serino, Maria Rita Fontana, Danilo Gomes Moriel
  • Surfactant-free, water-free formable composition and breakable foams and their uses
    Patent number: 10029013
    Abstract: A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or More other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: July 24, 2018
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
  • Construction of a quadruple enterotoxin-deficient mutant of bacillus thuringiensis
    Patent number: 10017771
    Abstract: Some HBL and NHE enterotoxins are known to cause food-borne diseases in humans. Enterotoxin-deficient mutants of member strains of the Bacillus cereus group that do not produce HBL, HBLa1, HBLa2, or NHE enterotoxins are disclosed. Enterotoxin-deficient mutants are suitable for use as biocontrol agents. Methods for making the mutants and for using the mutants are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: July 10, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jo Emily Handelsman, Amy Klimowicz, Changhui Guan
  • Neutralised cationic polymer, composition containing said polymer and a cosmetic treatment method
    Patent number: 10004923
    Abstract: The invention relates to an ethylene cationic polymer comprising at least one primary, secondary or tertiary protonable amine function which is at least partially neutralized by a polymer organic acid neutralizing agent which contains at least one carboxylic, sulphonic and/or phosphonic acid function. Said invention also relates to a cosmetic or pharmaceutical composition comprising said neutralized polymer in a physiologically acceptable medium, in particular, cosmetically or pharmaceutically acceptable medium. A method for cosmetically treating keratinic materials, such as a body of face skin, nails, hairs, eyebrows and/or eyelashes, consisting in applying the inventive cosmetic composition to said keratinic materials is also disclosed.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: June 26, 2018
    Assignee: L'OREAL
    Inventors: Nathalie Mougin, Gwenaëlle Jegou
  • Immune response modifier compositions and methods
    Patent number: 10005772
    Abstract: The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: June 26, 2018
    Assignee: 3M Innovative Properties Company
    Inventors: Doris Stoermer, George W. Griesgraber, Tushar A. Kshirsagar
  • Multivalent pneumococcal polysaccharide-protein conjugate composition
    Patent number: 9981045
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 29, 2018
    Assignee: Wyeth LLC
    Inventor: A. Krishna Prasad
  • Methods and compositions for treating lupus
    Patent number: 9962400
    Abstract: The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the compound is in an amount less than sufficient to substantially inhibit cyclin dependent kinases.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: May 8, 2018
    Assignee: Natrogen Therapeutics International, Inc.
    Inventors: Longgui Wang, Simon K. Mencher
  • Sustained release delivery of active agents to treat glaucoma and ocular hypertension
    Patent number: 9949942
    Abstract: The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s).
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: April 24, 2018
    Assignee: Mati Therapeutics Inc.
    Inventor: Zuhal Butuner
  • Tofacitinib oral sustained release dosage forms
    Patent number: 9937181
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 10, 2018
    Assignee: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C Stock
  • Biogel
    Patent number: 9913876
    Abstract: A biogel, and kits, agents, and methods for formation of the biogel are described. The biogel can be used for a variety of applications, including haemostasis, wound sealing, tissue engineering or localized drug delivery.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: March 13, 2018
    Assignee: Haemostatix Limited
    Inventor: Greg Walker
  • Use of a holotoxin to reduce endoplasmic reticulum-associated degradation of misfolded proteins
    Patent number: 9901612
    Abstract: The present invention provides a method of blocking endoplasmic reticulum associated degradation of functional but misfolded proteins.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: February 27, 2018
    Assignee: THE HOSPITAL FOR SICK CHILDREN
    Inventor: Clifford Lingwood
  • Anti-wall teichoic antibodies and conjugates
    Patent number: 9895450
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: February 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Anti-wall teichoic antibodies and conjugates
    Patent number: 9884126
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 6, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
    Patent number: 9878043
    Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: January 30, 2018
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer Macdiarmid
  • Endolysins active against bacteria, pharmaceutical compositions, and methods relating thereto
    Patent number: 9872893
    Abstract: The present invention relates to methods of treating or preventing a bacterial disease or infection, antibacterial compositions, and antibacterial surfaces, including isolated endolysin polypeptides from bacteriophage GRCS.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: January 23, 2018
    Assignee: University of Maryland College Park
    Inventor: Daniel C. Nelson
  • Hypo- and hyper-acetylated meningococcal capsular saccharides
    Patent number: 9827301
    Abstract: Capsular saccharides derived from serogroups W135 and Y of Neisseria meningitidis have altered levels of O-acetylation at the 7 and 9 positions of their sialic acid residues, and can be used to make immunogenic compositions. Relative to unmodified native saccharides, derivatives of the invention are preferentially selected during conjugation to carrier proteins, and conjugates of the derivatives show improved immunogenicity compared to native polysaccharides.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: November 28, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Paolo Costantino, Francesco Berti
  • CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
    Patent number: 9809824
    Abstract: The present invention provides a CpG oligonucleotide prodrug that includes a thermolabile substituent on at least one nucleotide thereof. The present invention also provides compositions that include a carrier and a therapeutically effective amount of at least one CpG oligonucleotide prodrug. The present invention further provides therapeutic methods of using such thermolabile CpG oligonucleotide prodrugs and compositions thereof. The present invention further provides a method of inhibiting tetrad formation in a CpG oligonucleotide by functionalizing the CpG oligonucleotide with one or more thermolabile substituents.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: November 7, 2017
    Assignee: The United States of America, Represented by the Secretary, Department of Health and Human Services
    Inventors: Daniela Verthelyi, Serge L. Beaucage, Andrzej Grajkowski
  • Anti-wall teichoic antibodies and conjugates
    Patent number: 9803002
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: October 31, 2017
    Assignee: Genentench, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen